Biocryst Pharmaceuticals (BCRX) Cash & Current Investments (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has 17 years of Cash & Current Investments data on file, last reported at $67.7 million in Q1 2026.

• Quarterly Cash & Current Investments fell 64.42% year-over-year to $67.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67.7 million (down 64.42% YoY) and the FY2025 annual result came in at $185.2 million, down 42.27% from the prior year.
• Cash & Current Investments declined to $67.7 million in Q1 2026, from $185.2 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $443.5 million in Q1 2022 to a low of $67.7 million in Q1 2026.
• A 5-year average of $277.2 million and a median of $248.3 million in 2023 frame the typical range for Cash & Current Investments.
• The widest YoY moves for Cash & Current Investments: up 2439.62% in 2022, down 76.16% in 2022.
• Tracing BCRX's Cash & Current Investments over 5 years: stood at $121.0 million in 2022, then jumped by 221.44% to $389.0 million in 2023, then slipped by 17.52% to $320.8 million in 2024, then sank by 42.27% to $185.2 million in 2025, then sank by 63.47% to $67.7 million in 2026.
• The last three Cash & Current Investments figures came in at $67.7 million (Q1 2026), $185.2 million (Q4 2025), and $212.9 million (Q3 2025), per Business Quant data.